Please login to the form below

Not currently logged in
Email:
Password:

Data supports Actemra's effectiveness

New two-year data has shown the effectiveness of Actemra in inhibiting structural damage to the joints of patients with rheumatoid arthritis, Roche has announced

New two-year data has shown the effectiveness of Actemra (tocilizumab) in inhibiting structural damage to the joints of patients with rheumatoid arthritis (RA), Roche has announced.

The Swiss drug maker said the data also improved patients' ability to perform everyday activities and helped maintain high remission rates.

Included in the data, x-rays of bone erosions and a narrowing of joint spaces showed that more patients treated with Actemra in combination with the current therapy, methotrexate, saw a significant inhibition in structural damage during 24 months of treatment when compared to patients in a control group.

The randomised LITHE study involved 1,196 patients with moderate to severe RA who previously had an inadequate response to methotrexate. Patients were administered either Actemra once every four weeks in a combination with methotrexate, or methotrexate alone.

Full data from the trial will be used to support regulatory filings for labelling claims. Actemra is currently already approved in Japan and Europe for the above usage.

26th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics